多效固定剂量复方制剂策略提升心血管预防指南达标率:随机临床试验荟萃分析
该研究对三项随机临床试验进行个体参与者数据荟萃分析,比较含阿司匹林、他汀和降压药的多效固定剂量复方制剂策略与常规治疗对既往心血管事件或高危患者达到2016年ESC指南血压、LDL胆固醇和抗血小板治疗目标的影响。共纳入3140例患者,结果显示复方制剂组在12个月时达到血压、LDL及三项指标同时达标的比例均显著高于常规治疗组,尤其在基线治疗不足的患者中获益更明显。
要点
- 复方制剂策略较常规治疗显著提高血压、LDL及三项指南目标同时达标率。
- 基线治疗强度越低,复方制剂策略的达标获益越大。
- 两组抗血小板治疗依从性无差异,均约96%。
核心结论
- 基于多效固定剂量复方制剂的治疗策略较常规治疗显著改善血压、LDL胆固醇和抗血小板治疗三项ESC指南目标的 simultaneously 达标率,尤其在基线治疗不足的患者中获益更明显。
研究设计与样本
- 三项随机临床试验的个体参与者数据荟萃分析,共纳入3140例来自澳大利亚、英国、印度、爱尔兰、荷兰和新西兰的既往心血管事件或高危患者(75%男性,平均年龄62岁,76%有既往心血管事件)。
主要发现
- 12个月时,复方制剂组达到血压目标的比例为62%,常规治疗组为58%(RR 1.08,95%CI 1.02–1.15)。
- 12个月时,复方制剂组达到LDL目标的比例为39%,常规治疗组为34%(RR 1.13,95%CI 1.02–1.25)。
- 12个月时,复方制剂组同时达到血压、LDL和抗血小板治疗三项目标的比例为24%,常规治疗组为19%(RR 1.27,95%CI 1.10–1.47)。
- 抗血小板治疗依从性两组均为96%(RR 1.00,95%CI 0.98–1.01)。
- 基线治疗强度存在异质性:基线使用3、2和0–1种治疗模式的患者同时达到三项指南目标的RR分别为1.10(95%CI 0.94–1.30,22% vs 20%)、1.62(95%CI 1.09–2.42,27% vs 17%)和3.07(95%CI 1.77–5.33,35% vs 11%)。
关键数值与推荐
- 2016年ESC指南目标:血压、LDL胆固醇和抗血小板治疗(后者仅适用于既往心血管事件患者)。
临床怎么用
- 对于既往心血管事件或高危患者,可考虑使用含阿司匹林、他汀和降压药的多效固定剂量复方制剂以提高指南目标达标率。
- 基线治疗不足的患者从复方制剂策略中获益更大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to determine the effect of polypill-based care on the achievement of 2016 European Society of Cardiology (ESC) guideline targets for blood pressure (BP), low-density lipoprotein (LDL) cholesterol and antiplatelet therapy. METHODS: We conducted an individual participant data meta-analysis of three randomised clinical trials that compared a strategy using a polypill containing aspirin, statin and antihypertensive therapy with usual care in patients with a prior cardiovascular disease (CVD) event or who were at high risk of their first event. Overall, the trials included 3140 patients from Australia, England, India, Ireland, the Netherlands and New Zealand (75% male, mean age 62 years and 76% with a prior CVD event). The primary outcome for this study was the proportion of people achieving ESC guideline targets for BP, LDL and antiplatelet therapy. RESULTS: Those randomised to polypill-based care were more likely than those receiving usual care to achieve recommended targets for BP (62% vs 58%, risk ratio (RR) 1.08, 95% CI 1.02 to 1.15), LDL (39% vs 34%, RR 1.13, 95% CI 1.02 to 1.25) and all three targets for BP, LDL and adherence to antiplatelet therapy (the latter only applicable to those with a prior CVD event) simultaneously (24% vs 19%, RR 1.27, 95% CI 1.10 to 1.47) at 12 months. There was no difference between groups in antiplatelet adherence (96% vs 96%, RR 1.00, 95% CI 0.98 to 1.01). There was heterogeneity by baseline treatment intensity such that treatment effects increased with the fewer the number of treatments being taken at baseline: for patients taking 3, 2 and 0-1 treatment modalities the RRs for reaching all three guideline goals simultaneously were 1.10 (95% CI 0.94 to 1.30, 22% vs 20%), 1.62 (95% CI 1.09 to 2.42, 27% vs 17%) and 3.07 (95% CI 1.77 to 5.33, 35% vs 11%), respectively. CONCLUSIONS: Polypill-based therapy significantly improved the achievement of all three ESC targets for BP, LDL and antiplatelet therapy compared with usual care, particularly among those undertreated at baseline.
引用
- Selak V, Webster R, Stepien S, et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart. 2018. PMID: 29954855. doi:10.1136/heartjnl-2018-313108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。